In a recent blog post – AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.
These novel reagents empower research by enhancing the efficiency, accuracy, and reproducibility of scientific investigations.
A collaborative effort led by Dr. Wenjing Wang at the University of Michigan and Dr. Xiaobo Mao of Johns Hopkins University School of Medicine has made exciting advances in the development of potential therapeutics…
Cambridge, UK 23 February 2024
We are pleased to announced the shortlist for the One Nucleus Awards 2024.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders. “Performance of the Year” being recognised in each category. The awards criteria recognise success between 1 December 2022 – 30 November 2023.
Best Performing Facilities Provider of the Year:
Babraham Research Campus
Bruntwood SciTech
Stevenage Bioscience Catalyst
Best Performing Investor of the Year:
Cambridge…
Cambridge, UK 23 February 2024 - We are thrilled to announce the winners of the One Nucleus Boston Bootcamp competition aimed at providing a focused ‘Getting US-ready’ experience.
Congratulations to:
The competition attracted a diverse range of entries from across the UK showcasing a breadth of innovation in R&D drug discovery and platform technologies enhancing the R&D efforts of others.
All applicants were extremely high quality and exemplars of the proposition quality and approach likely to attract interest from the MA ecosystem. Judges commented that the Presentation…
Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-cell engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial. This trial is evaluating the Company’s first-in-class biologic CAR T-cell engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
Cancer Research UK’s Centre for Drug Development is sponsoring and conducting…
Biocair, an award-winning life science logistics expert, is pleased to announce the opening of its office in Bangalore, the company’s fourth office in India. Spread over 2500 square feet, the new office was inaugurated by Neha Naik, General Manager Biocair India, on February 13 alongside key customers and key partners. Biocair first established operations in the country in 2021 with its corporate office in Mumbai and other locations in New Delhi and Chennai.
Ms. Naik comments “The pharma business in India is worth approximately $50 billion and is expected to reach $100 billion by 2030 - we…
• Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases
• Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year
OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, PrecisionLife, and leading US multi-specialty healthcare center, Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic…
We recently conducted a survey to help us and the businesses we represent better understand the future of recruitment.
In light of the enduring challenges posed by the cost of living crisis for both job seekers and organisations, our goal was to collect valuable data. We hope this information empowers businesses to make informed decisions and shape effective recruitment strategies, aiding their success in a volatile market, not only for 2024 but for the years ahead.
Summary of findings:
Our survey results illuminate the landscape for 2024, offering insights into both hurdles and potential…
Following the success of three previous events of a similar format, the Anglia Innovation Partnership (AIP) team, the science park management company, at Norwich Research Park will continue to hold enterprise showcase events throughout 2024 to demonstrate the strength of enterprise, innovation, research and collaboration across the campus that has been delivered through the ongoing campus-wide enterprise strategy.
The previous event held in November 2023 organised in collaboration with the UEA and Royal Society Entrepreneur in Residence, was an enormous success, with an exciting format…
Expanded solutions for seamless stem cell research
AMSBIO, a leading provider of innovative products and services for the life sciences community, announces the launch of its Expanded Stem Cell Synergy Solutions.
Over the last two decades AMSBIO has established itself as a leading international supplier of solutions for streamlined and efficient ES/iPS Cell Culture using feeder-free StemFit® media and iMatrix recombinant laminin extracellular matrices. Backed by knowledgeable support teams in the UK, USA, and Germany – AMSBIO has expanded its products and services across the entire stem cell…
In October 2023, the Financial Reporting Council (FRC) announced a delay to the publication and effective date of the future changes to UK GAAP from its periodic review.
The revised suite of standards reflecting the second periodic review of UK GAAP is now expected to be issued in the first half of 2024 and implemented not before periods commencing on or after 1 January 2026, instead of 1 January 2025 as originally planned.
Understanding the delay
The delayed issue date has provided the FRC with more time as it considers over 50 responses to its consultation on the…